SXTP Stock Price | 60 Degrees Pharmaceuticals, Inc. Common Stock P/E, Revenue, EPS, & Forecasts

60 Degrees Pharmaceuticals, Inc. Common Stock • SXTP

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About 60 Degrees Pharmaceuticals, Inc. Common Stock

Ticker

SXTP

Trading on

NASDAQ

ISIN

US83006G1040

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Geoffrey Stuart Dow Ph.D.

Headquarters

1025 Connecticut Avenue NW, Washington, DC, United States, 20036

Employees

Website

60degreespharma.com

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.

Metrics

BasicAdvanced

Market cap

$3.2M

P/E ratio

EPS

-$18.55

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-9.7M

Ex dividend date

Price & volume

Market cap

$3.2M

Average daily volume

0.2M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

4.65

Price to book

Earnings

EPS

-$18.55

EPS estimate (current quarter)

-$3.25

EPS estimate (next quarter)

-$3.35

EBITDA

$-9.7M

Revenues (TTM)

$0.7M

Revenues per share (TTM)

$1.50

Technicals

Beta

52-week High

$23.94

52-week Low

$1.41

50-day moving average

$2.30

200-day moving average

$4.70

Short ratio

0.01

Short %

1.98%

Management effectiveness

ROE (TTM)

181.78%

ROA (TTM)

89.67%

Profit margin

0.00%

Gross profit margin

$-2.9M

Operating margin

794.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

512.20%

Share stats

Outstanding Shares

1.5M

Float

1.3M

Insiders %

4.33%

Institutions %

3.72%

Analyst Insights & forecasts

50% Buy

50% Hold

0% Sell

Based on information from 2 analysts.

Average price target

$5.80

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

$0.03

-$0.15

120.00%

Q1 • 24Beat

-$20.55

-$8.40

144.70%

Q2 • 24Beat

-$4.34

-$4.35

0.28%

Q3 • 24Beat

-$8.48

-$3.25

160.92%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0.1M

$-2.2M

1,596.38%

Q3 • 24

$0.2M

$-2M

885.89%

Q4 • 24

70.63%

5.31%

44.51%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$7.4M

$1.5M

19.65%

Q3 • 24

$5.8M

$1.8M

31.33%

Q4 • 24

22.39%

23.75%

59.45%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$2.3M

$-1.7M

$5.2M

$-1.7M

Q3 • 24

$-1.6M

$-0M

$0M

$-1.6M

Q4 • 24

170.35%

99.88%

99.98%

4.63%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a 60 Degrees Pharmaceuticals, Inc. Common Stock share?

60 Degrees Pharmaceuticals, Inc. Common Stock shares are currently traded for undefined per share.

How many shares does 60 Degrees Pharmaceuticals, Inc. Common Stock have?

60 Degrees Pharmaceuticals, Inc. Common Stock currently has 1.5M shares.

Does 60 Degrees Pharmaceuticals, Inc. Common Stock pay dividends?

No, 60 Degrees Pharmaceuticals, Inc. Common Stock doesn't pay dividends.

What is 60 Degrees Pharmaceuticals, Inc. Common Stock 52 week high?

60 Degrees Pharmaceuticals, Inc. Common Stock 52 week high is $23.94.

What is 60 Degrees Pharmaceuticals, Inc. Common Stock 52 week low?

60 Degrees Pharmaceuticals, Inc. Common Stock 52 week low is $1.41.

What is the 200-day moving average of 60 Degrees Pharmaceuticals, Inc. Common Stock?

60 Degrees Pharmaceuticals, Inc. Common Stock 200-day moving average is $4.70.

Who is 60 Degrees Pharmaceuticals, Inc. Common Stock CEO?

The CEO of 60 Degrees Pharmaceuticals, Inc. Common Stock is Dr. Geoffrey Stuart Dow Ph.D..

How many employees 60 Degrees Pharmaceuticals, Inc. Common Stock has?

60 Degrees Pharmaceuticals, Inc. Common Stock has 3 employees.

What is the market cap of 60 Degrees Pharmaceuticals, Inc. Common Stock?

The market cap of 60 Degrees Pharmaceuticals, Inc. Common Stock is $3.2M.

What is the P/E of 60 Degrees Pharmaceuticals, Inc. Common Stock?

The current P/E of 60 Degrees Pharmaceuticals, Inc. Common Stock is null.

What is the EPS of 60 Degrees Pharmaceuticals, Inc. Common Stock?

The EPS of 60 Degrees Pharmaceuticals, Inc. Common Stock is -$18.55.

What is the PEG Ratio of 60 Degrees Pharmaceuticals, Inc. Common Stock?

The PEG Ratio of 60 Degrees Pharmaceuticals, Inc. Common Stock is null.

What do analysts say about 60 Degrees Pharmaceuticals, Inc. Common Stock?

According to the analysts 60 Degrees Pharmaceuticals, Inc. Common Stock is considered a buy.